TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma.

Trial Profile

TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Trabectedin (Primary) ; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRUSTS
  • Most Recent Events

    • 09 Nov 2016 This trial has been completed in Poland (End date:2016-04-16) as per European Clinical Trials Database record.
    • 24 Jun 2016 The trial was completed in Denmark.
    • 21 Jun 2016 The trial was completed in Germany (end date:2016-04-16).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top